BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
304.51 USD
+0.78 (+0.26%)
304.51 USD
0 (0%)
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
BIO had a positive operating cash flow in the past year.
In multiple years BIO reported negative net income over the last 5 years.
In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
BIO has a Return On Assets (-6.97%) which is in line with its industry peers.
The Return On Equity of BIO (-10.03%) is comparable to the rest of the industry.
BIO has a Return On Invested Capital of 2.26%. This is in the better half of the industry: BIO outperforms 61.40% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Operating Margin value of 10.27%, BIO is doing good in the industry, outperforming 70.18% of the companies in the same industry.
BIO's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 52.42%, BIO is doing good in the industry, outperforming 63.16% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BIO has been reduced compared to 1 year ago.
Compared to 5 years ago, BIO has less shares outstanding
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 3.38. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
BIO's Altman-Z score of 3.38 is fine compared to the rest of the industry. BIO outperforms 68.42% of its industry peers.
BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
BIO has a better Debt to FCF ratio (3.57) than 77.19% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.38 |
ROIC/WACC0.22
WACC10.46%
2.3 Liquidity
BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Current ratio of 5.44. This is amongst the best in the industry. BIO outperforms 85.96% of its industry peers.
A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
BIO's Quick ratio of 3.94 is fine compared to the rest of the industry. BIO outperforms 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.90% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
The Earnings Per Share is expected to decrease by -2.66% on average over the next years.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated quite expensively with a Price/Earnings ratio of 29.54.
BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 75.44% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 29.56, BIO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 68.42% of the companies are valued more expensively.
BIO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.54 | ||
| Fwd PE | 29.56 |
4.2 Price Multiples
BIO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO is cheaper than 78.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.39 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.77
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
304.51
+0.78 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change1.8%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.21B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (18.91%)
Short Float %4.91%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)8.45%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)-2.34%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.54 | ||
| Fwd PE | 29.56 | ||
| P/S | 3.21 | ||
| P/FCF | 24.39 | ||
| P/OCF | 16.71 | ||
| P/B | 1.22 | ||
| P/tB | 1.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.39%
EPS(NY)10.3
Fwd EY3.38%
FCF(TTM)12.48
FCFY4.1%
OCF(TTM)18.22
OCFY5.98%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.77
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.38 |
F-Score5
WACC10.46%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y14.51%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
What is the valuation status of BIO-RAD LABORATORIES-A (BIO) stock?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES-A (BIO) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 29.54 and the Price/Book (PB) ratio is 1.22.
What is the expected EPS growth for BIO-RAD LABORATORIES-A (BIO) stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.19% in the next year.